Novel Biomarkers Related Xuebijing Injection Improves Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-30

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value for the precise treatment of sepsis and the research and development of new drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions（EXIT-SEP REAL）

NCT07069894

Sepsis

NOT_YET_RECRUITING

The Efficacy of Xuebijing Injection on Sepsis

NCT03238742

Sepsis

COMPLETED PHASE4

Pharmacokinetics of XueBiJing in Patients With Sepsis

NCT03475732

Sepsis Septic Shock Community Acquired Pneumonia

COMPLETED NA

Clinical Research on Shenfu Injection in Septic Patients

NCT06157320

Sepsis

RECRUITING NA

Effect of Renin-Angiotensin System on Platelet in Patient With Sepsis

NCT03952390

Sepsis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xuebijing treatment group

Based on the standard treatment group Xuebijing injection was added.

No interventions assigned to this group

Standard treatment group

Patients with sepsis are given standard treatment according to international guidelines for the management of sepsis and septic shock

No interventions assigned to this group

Healthy Volunteer Group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Meeting the Sepsis 3.0 diagnostic criteria;
2. SOFA score ≥ 2 and \< 13;
3. Signed informed consent.

Exclusion Criteria

1. Age \<18 years or \>75 years;
2. Pregnant or lactating women;
3. Presence of severe primary diseases including malignant tumors severe hematologic disorders and HIV infection;
4. Current use of immunosuppressants or history of organ transplantation within the past 6 months;
5. Comorbidities that significantly affect vascular endothelial structure and function such as acute myocardial infarction.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes